JPWO2020264208A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020264208A5 JPWO2020264208A5 JP2021576274A JP2021576274A JPWO2020264208A5 JP WO2020264208 A5 JPWO2020264208 A5 JP WO2020264208A5 JP 2021576274 A JP2021576274 A JP 2021576274A JP 2021576274 A JP2021576274 A JP 2021576274A JP WO2020264208 A5 JPWO2020264208 A5 JP WO2020264208A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- amino acid
- acid sequence
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025138827A JP2026000901A (ja) | 2019-06-26 | 2025-08-22 | Ｅｇｆｒ抗原結合断片およびそれを含む組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962866749P | 2019-06-26 | 2019-06-26 | |
| US62/866,749 | 2019-06-26 | ||
| US202063043486P | 2020-06-24 | 2020-06-24 | |
| US63/043,486 | 2020-06-24 | ||
| PCT/US2020/039682 WO2020264208A1 (en) | 2019-06-26 | 2020-06-25 | Egfr antigen binding fragments and compositions comprising same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025138827A Division JP2026000901A (ja) | 2019-06-26 | 2025-08-22 | Ｅｇｆｒ抗原結合断片およびそれを含む組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022538222A JP2022538222A (ja) | 2022-09-01 |
| JPWO2020264208A5 true JPWO2020264208A5 (https=) | 2023-07-04 |
| JP2022538222A5 JP2022538222A5 (https=) | 2023-07-04 |
| JP7847433B2 JP7847433B2 (ja) | 2026-04-17 |
Family
ID=74060335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576274A Active JP7847433B2 (ja) | 2019-06-26 | 2020-06-25 | Ｅｇｆｒ抗原結合断片およびそれを含む組成物 |
| JP2025138827A Pending JP2026000901A (ja) | 2019-06-26 | 2025-08-22 | Ｅｇｆｒ抗原結合断片およびそれを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025138827A Pending JP2026000901A (ja) | 2019-06-26 | 2025-08-22 | Ｅｇｆｒ抗原結合断片およびそれを含む組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230312729A1 (https=) |
| EP (1) | EP3990499A4 (https=) |
| JP (2) | JP7847433B2 (https=) |
| KR (1) | KR20220038356A (https=) |
| CN (1) | CN114729056A (https=) |
| AU (1) | AU2020303586A1 (https=) |
| CA (1) | CA3143522A1 (https=) |
| CL (1) | CL2021003435A1 (https=) |
| CO (1) | CO2022000404A2 (https=) |
| IL (1) | IL289100A (https=) |
| MX (1) | MX2021015882A (https=) |
| WO (1) | WO2020264208A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021023988A2 (pt) | 2019-05-31 | 2022-04-19 | Zymeworks Inc | Métodos de uso de um construto de ligação ao antígeno biespecífico que tem como alvo her2 para o tratamento de cânceres no trato biliar |
| JP2024518539A (ja) | 2020-04-04 | 2024-05-01 | ジャナックス セラピューティクス，インク． | 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法 |
| JP2023531494A (ja) | 2020-06-25 | 2023-07-24 | アムニクス ファーマシューティカルズ， インコーポレイテッド | Ｈｅｒ－２標的化二重特異性組成物ならびにその作製および使用のための方法 |
| EP4337794A4 (en) * | 2021-05-11 | 2025-07-02 | Janux Therapeutics Inc | ANTIBODIES TARGETING EGFR AND CD3 AND THEIR USES |
| CN121426967A (zh) * | 2023-02-10 | 2026-01-30 | 阿穆尼克斯制药公司 | 靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法 |
| EP4683718A1 (en) | 2023-04-17 | 2026-01-28 | Amunix Pharmaceuticals, Inc. | Compositions targeting epidermal growth factor receptor and methods for making and using the same |
| WO2025122957A1 (en) | 2023-12-08 | 2025-06-12 | Amunix Pharmaceuticals, Inc. | Protease activatable cytokines and methods for making and using the same |
| TW202547886A (zh) * | 2024-02-02 | 2025-12-16 | 美商黛安瑟斯醫療運營公司 | 用於治療ｃ１ｓ介導的疾病和病症的組成物、劑量和方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006301492B2 (en) * | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| JP5685535B2 (ja) * | 2008-08-18 | 2015-03-18 | ファイザー インコーポレイティッド | Ｃｃｒ２に対する抗体 |
| AU2014206217B2 (en) * | 2009-02-03 | 2015-09-17 | Amunix Pharmaceuticals, Inc. | Extended recombinant polypeptides and compositions comprising same |
| US20140155581A1 (en) * | 2011-07-06 | 2014-06-05 | Medimmune, Llc | Methods For Making Multimeric Polypeptides |
| EP2768858B1 (en) * | 2011-10-18 | 2018-08-01 | Emory University | Antibodies directed against influenza |
| US20150259420A1 (en) * | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| KR102162324B1 (ko) * | 2015-10-30 | 2020-10-07 | 제넨테크, 인크. | 항-HtrA1 항체 및 이의 사용 방법 |
| SG10201912565QA (en) * | 2016-09-29 | 2020-02-27 | Amgen Inc | Low-viscosity antigen binding proteins and methods of making them |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
-
2020
- 2020-06-25 CA CA3143522A patent/CA3143522A1/en active Pending
- 2020-06-25 AU AU2020303586A patent/AU2020303586A1/en not_active Abandoned
- 2020-06-25 KR KR1020227002556A patent/KR20220038356A/ko active Pending
- 2020-06-25 WO PCT/US2020/039682 patent/WO2020264208A1/en not_active Ceased
- 2020-06-25 US US17/621,978 patent/US20230312729A1/en active Pending
- 2020-06-25 MX MX2021015882A patent/MX2021015882A/es unknown
- 2020-06-25 EP EP20833213.0A patent/EP3990499A4/en active Pending
- 2020-06-25 CN CN202080061211.XA patent/CN114729056A/zh active Pending
- 2020-06-25 JP JP2021576274A patent/JP7847433B2/ja active Active
-
2021
- 2021-12-19 IL IL289100A patent/IL289100A/en unknown
- 2021-12-21 CL CL2021003435A patent/CL2021003435A1/es unknown
-
2022
- 2022-01-19 CO CONC2022/0000404A patent/CO2022000404A2/es unknown
-
2025
- 2025-08-22 JP JP2025138827A patent/JP2026000901A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114341186B (zh) | 双特异性抗LRRC15和CD3ε抗体 | |
| EP2691416B1 (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
| CN115605504A (zh) | 新型il-21前药及其使用方法 | |
| NZ717476A (en) | Anti-garp protein and uses thereof | |
| ES2974323T3 (es) | Anticuerpo biespecífico tetravalente frente a PD-1 y VEGF, método de preparación para el mismo y uso del mismo | |
| WO2014106015A2 (en) | Multivalent binding protein compositions | |
| DK2921503T3 (en) | Human antibody to human epidermal growth factor receptor and coding gene and its use | |
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| PE20230408A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| KR20160131061A (ko) | 항-mcam 항체 및 관련된 사용 방법 | |
| JP2026004299A5 (https=) | ||
| JP7525499B2 (ja) | ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法 | |
| CN113968910A (zh) | 四价对称双特异性抗体 | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| TW201934578A (zh) | 治療方法 | |
| JPWO2020264208A5 (https=) | ||
| EP4263584A1 (en) | Combination therapy for the treatment of cancer | |
| JP2022513228A (ja) | 抗ペリオスチン抗体及びその使用 | |
| JP2023506162A (ja) | 抗ｂｃｍａ／抗４－１ｂｂ二重特異性抗体及びその用途 | |
| JPWO2021263058A5 (https=) | ||
| JP2025527160A (ja) | 多重特異性抗体およびその使用 | |
| RU2022101309A (ru) | Антигенсвязывающие фрагменты для egfr и композиции, содержащие их | |
| US20220127362A1 (en) | Tetravalent bispecific antibody against pd-1/lag-3, preparation method therefor, and use thereof | |
| CN120225557A (zh) | 特异于跨膜激活物和caml相互作用物(taci)的抗原结合蛋白 | |
| KR20250039354A (ko) | 감마-델타 t 세포 수용체에 결합하는 항체를 포함하는 조성물 |